Related Experiment Videos
Circulating colony-forming cells in different stages of chronic myelocytic leukemia
Insights
Circulating granulocyte-macrophage colony-forming cells (CFU-c) are elevated in chronic myelocytic leukemia (CML) chronic stages but not always deficient in blastic stages. CFU-c levels in advanced CML stages do not correlate with disease status or cell counts.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Chronic myelocytic leukemia (CML) is a myeloproliferative neoplasm characterized by uncontrolled proliferation of myeloid cells.
- Circulating granulocyte-macrophage colony-forming cells (CFU-c) are key indicators of hematopoietic stem and progenitor cell activity.
- Previous studies reported conflicting findings regarding CFU-c levels in advanced CML stages.
Purpose of the Study:
- To investigate the incidence of circulating CFU-c in patients with CML across different disease stages.
- To compare CFU-c levels in CML patients with healthy controls.
- To explore the correlation between CFU-c levels and clinical parameters in CML.
Main Methods:
- Collected peripheral blood samples from 60 CML patients in various stages (chronic, accelerated-resistant, blastic) and healthy controls.
- Determined CFU-c incidence using standard in vitro culture techniques.
- Analyzed correlations between CFU-c levels and white blood cell count, immature cell percentage, clinical status, and survival.
Main Results:
- Circulating CFU-c were uniformly increased in the uncontrolled chronic stage of CML.
- CFU-c levels decreased to normal during remission.
- Contrary to some reports, normal to greatly increased CFU-c formation was observed in accelerated-resistant and blastic stages.
- CFU-c incidence in advanced CML stages did not correlate with white blood cell count, immature cells, clinical status, or survival.
- No direct relationship was found between CFU-c incidence and the percentage of circulating myeloblasts and promyelocytes.
Conclusions:
- CFU-c levels in CML vary significantly across disease stages, with increased incidence in the chronic phase and variable levels in advanced stages.
- The discrepancy in CFU-c findings in blastic CML suggests potentially more stringent growth requirements for CFU-c in terminal disease.
- CFU-c incidence in advanced CML stages is not a reliable indicator of disease burden or prognosis.
Abstract:
The incidence of circulating granulocyte-macrophage colony-forming cells (CFU-c) was determined in 60 patients in different stages of chronic myelocytic leukemia (CML). Like others, we found uniformly increased circulating CFU-c during the uncontrolled chronic stage, decreasing to values indistinguishable from those of healthy controls during remission. Unlike some investigators who described grossly deficient colony formation during the blastic stage of CML, we found normal to greatly increased colony formation in the accelerated-resistant and blastic stages. The fact that laboratories using somewhat different culture techniques obtain similar results with specimens from the chronic stage of CML but divergent results with specimens from terminal stage disease suggests that CFU-c from blastic disease have more fastidious growth requirements than do those from chronic stage disease or from normal subjects. In contrast to the correlation between CFU-c and disease status in the chronic stage of CML, CFU-c incidence in the accelerated-resistant and blastic stages of the disease did not correlate with white blood cell count, percentage of immature cells, clinical status, or survival. There was no correlation between the percentage of myeloblasts and promyelocytes in circulating blood and the incidence of CFU-c in any stage of CML, which suggests that no direct relationship exists between clonogenic units and the number of identifiable proliferating cells.